Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Translational Stroke Research
Published in: Translational Stroke Research 1/2017

Open Access 01-02-2017 | Review

The Cerebrovascular-Chronic Kidney Disease Connection: Perspectives and Mechanisms

Authors: Wei Ling Lau, Branko N. Huisa, Mark Fisher

Published in: Translational Stroke Research | Issue 1/2017

Login to get access

Abstract

Chronic kidney disease (CKD) is an independent risk factor for the development of cerebrovascular disease, particularly small vessel disease which can manifest in a variety of phenotypes ranging from lacunes to microbleeds. Small vessel disease likely contributes to cognitive dysfunction in the CKD population. Non-traditional risk factors for vascular injury in uremia include loss of calcification inhibitors, hyperphosphatemia, increased blood pressure variability, elastinolysis, platelet dysfunction, and chronic inflammation. In this review, we discuss the putative pathways by which these mechanisms may promote cerebrovascular disease and thus increase risk of future stroke in CKD patients.
Literature
1.
Chen YC et al. Chronic kidney disease itself is a causal risk factor for stroke beyond traditional cardiovascular risk factors: a nationwide cohort study in Taiwan. PLoS One. 2012;7(4):e36332.PubMedPubMedCentralCrossRef
2.
Koren-Morag N, Goldbourt U, Tanne D. Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology. 2006;67(2):224–8.PubMedCrossRef
3.
Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol. 2014;13(8):823–33.PubMedCrossRef
4.
Naganuma T, Takemoto Y. New aspects of cerebrovascular diseases in dialysis patients. Contrib Nephrol. 2015;185:138–46.PubMed
5.
Weiner DE et al. Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. Am J Kidney Dis. 2009;53(3):438–47.PubMedCrossRef
6.
Khatri M et al. Chronic kidney disease is associated with white matter hyperintensity volume: the Northern Manhattan Study (NOMAS). Stroke. 2007;38(12):3121–6.PubMedPubMedCentralCrossRef
7.
Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341:c3666.PubMedPubMedCentralCrossRef
8.
Eldehni MT, McIntyre CW. Are there neurological consequences of recurrent intradialytic hypotension? Semin Dial. 2012;25(3):253–6.PubMedCrossRef
9.
Prohovnik I et al. Cerebrovascular effects of hemodialysis in chronic kidney disease. J Cereb Blood Flow Metab. 2007;27(11):1861–9.PubMedCrossRef
10.
11.
Ninomiya T et al. Proteinuria and stroke: a meta-analysis of cohort studies. Am J Kidney Dis. 2009;53(3):417–25.PubMedCrossRef
12.
13.
Murray AM et al. Cognitive impairment in hemodialysis patients is common. Neurology. 2006;67(2):216–23.PubMedCrossRef
14.
15.
Izzo JL, Sica D, Black HR. Hypertension primer: the essentials of high blood pressure: basic science, population science, and clinical management. Philadelphia: Lippincott Williams & Wilkins; 2007.
16.
Ito S et al. Strain vessel hypothesis: a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res. 2009;32(2):115–21.PubMedCrossRef
17.
18.
Moritz AR, Oldt MR. Arteriolar sclerosis in hypertensive and non-hypertensive individuals. Am J Pathol. 1937;13(5):679–728.7.PubMedPubMedCentral
19.
20.
O’Sullivan M et al. Patterns of cerebral blood flow reduction in patients with ischemic leukoaraiosis. Neurology. 2002;59(3):321–6.PubMedCrossRef
21.
22.
Johnson RJ, Feehally J, Floege J. Comprehensive clinical nephrology. 5th ed. Philadelphia: Elsevier Health Sciences; 2014.
23.
Liu W et al. Different impacts of blood pressure variability on the progression of cerebral microbleeds and white matter lesions. Stroke. 2012;43(11):2916–22.PubMedCrossRef
24.
Tanner RM et al. Association between 24-hour blood pressure variability and chronic kidney disease: a cross-sectional analysis of African Americans participating in the Jackson heart study. BMC Nephrol. 2015;16:84.PubMedPubMedCentralCrossRef
25.
Chang TI, et al. Visit-to-visit variability of blood pressure and death, end-stage renal disease, and cardiovascular events in patients with chronic kidney disease. J Hypertens. 2016;34:244–52.
26.
Brunelli SM et al. Association between long-term blood pressure variability and mortality among incident hemodialysis patients. Am J Kidney Dis. 2008;52(4):716–26.PubMedCrossRef
27.
Flythe JE, Brunelli SM. Blood pressure variability and dialysis: variability may not always be the spice of life. J Am Soc Nephrol. 2014;25(4):650–3.PubMedPubMedCentralCrossRef
28.
Chesterton LJ et al. Reduced baroreflex sensitivity is associated with increased vascular calcification and arterial stiffness. Nephrol Dial Transplant. 2005;20(6):1140–7.PubMedCrossRef
29.
Chesterton LJ et al. Categorization of the hemodynamic response to hemodialysis: the importance of baroreflex sensitivity. Hemodial Int. 2010;14(1):18–28.PubMedCrossRef
30.
31.
Sedaghat S, et al. Kidney function and cerebral blood flow: the Rotterdam study. J Am Soc Nephrol. 2015;27:715–21.
32.
Eldehni MT, Odudu A, McIntyre CW. Randomized clinical trial of dialysate cooling and effects on brain white matter. J Am Soc Nephrol. 2015;26(4):957–65.PubMedCrossRef
33.
34.
Toth-Manikowski SM, Sozio SM. Cooling dialysate during in-center hemodialysis: beneficial and deleterious effects. World J Nephrol. 2016;5(2):166–71.PubMedPubMedCentralCrossRef
35.
36.
Lau WL, Ix JH. Clinical detection, risk factors, and cardiovascular consequences of medial arterial calcification: a pattern of vascular injury associated with aberrant mineral metabolism. Semin Nephrol. 2013;33(2):93–105.PubMedCrossRef
37.
Jono S et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87(7):E10–7.PubMedCrossRef
38.
Steitz S et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89(12):1147–54.PubMedCrossRef
39.
40.
Tyson K et al. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol. 2003;23(3):489–94.PubMedCrossRef
41.
Li X, Yang H, Giachelli C. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res. 2006;98(7):905–12.PubMedCrossRef
42.
Crouthamel MH, et al. sodium-dependent phosphate cotransporters and phosphate-induced calcification of vascular smooth muscle cells: redundant roles for PiT-1 and PiT-2. Arterioscler Thromb Vasc Biol. 2013;33:2625–32.
43.
Shroff R et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol. 2010;21(1):103–12.PubMedPubMedCentralCrossRef
44.
Kalimo H et al. CADASIL: a common form of hereditary arteriopathy causing brain infarcts and dementia. Brain Pathol. 2002;12(3):371–84.PubMedCrossRef
45.
Tikka S et al. CADASIL mutations and shRNA silencing of NOTCH3 affect actin organization in cultured vascular smooth muscle cells. J Cereb Blood Flow Metab. 2012;32(12):2171–80.PubMedPubMedCentralCrossRef
46.
Craggs LJ et al. Microvascular pathology and morphometrics of sporadic and hereditary small vessel diseases of the brain. Brain Pathol. 2014;24(5):495–509.PubMedPubMedCentralCrossRef
47.
Hosaka N et al. Elastin degradation accelerates phosphate-induced mineralization of vascular smooth muscle cells. Calcif Tissue Int. 2009;85(6):523–9.PubMedCrossRef
48.
49.
Simionescu A, Philips K, Vyavahare N. Elastin-derived peptides and TGF-beta1 induce osteogenic responses in smooth muscle cells. Biochem Biophys Res Commun. 2005;334(2):524–32.PubMedCrossRef
50.
Smith ER et al. Elastin degradation is associated with progressive aortic stiffening and all-cause mortality in predialysis chronic kidney disease. Hypertension. 2012;59(5):973–8.PubMedCrossRef
51.
Chung AW et al. Matrix metalloproteinase-2 and -9 exacerbate arterial stiffening and angiogenesis in diabetes and chronic kidney disease. Cardiovasc Res. 2009;84(3):494–504.PubMedCrossRef
52.
Rosell A et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke. 2006;37(6):1399–406.PubMedCrossRef
53.
Adair JC et al. Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke. 2004;35(6):e159–62.PubMedCrossRef
54.
Shanahan CM et al. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest. 1994;93(6):2393–402.PubMedPubMedCentralCrossRef
55.
Murshed M et al. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol. 2004;165(5):625–30.PubMedPubMedCentralCrossRef
56.
Schurgers LJ et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol. 2010;5(4):568–75.PubMedPubMedCentralCrossRef
57.
Fleisch H et al. Inhibition of aortic calcification by means of pyrophosphate and polyphosphates. Nature. 1965;207(5003):1300–1.PubMedCrossRef
58.
Lomashvili K et al. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol. 2004;15(6):1392–401.PubMedCrossRef
59.
Lomashvili KA, Khawandi W, O’Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol. 2005;16(8):2495–500.PubMedCrossRef
60.
O’Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant. 2010;25(1):187–91.PubMedCrossRef
61.
Schinke T et al. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem. 1996;271(34):20789–96.PubMedCrossRef
62.
Heiss A et al. Hierarchical role of fetuin-A and acidic serum proteins in the formation and stabilization of calcium phosphate particles. J Biol Chem. 2008;283(21):14815–25.PubMedCrossRef
63.
Ketteler M et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361(9360):827–33.PubMedCrossRef
64.
Stenvinkel P et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int. 2005;67(6):2383–92.PubMedCrossRef
65.
Lau WL, Liu S, Vaziri ND. Chronic kidney disease results in deficiency of ABCC6, the novel inhibitor of vascular calcification. Am J Nephrol. 2014;40(1):51–5.PubMedCrossRef
66.
Gattineni J et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol. 2009;297(2):F282–91.PubMedPubMedCentralCrossRef
67.
Chen T et al. The role and mechanism of α-Klotho in the calcification of rat aortic vascular smooth muscle cells. Biomed Res Int. 2015;2015:194362.PubMedPubMedCentral
68.
69.
Wang H et al. Peripheral administration of fetuin-A attenuates early cerebral ischemic injury in rats. J Cereb Blood Flow Metab. 2010;30(3):493–504.PubMedCrossRef
70.
Weikert C et al. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008;118(24):2555–62.PubMedCrossRef
71.
Arking DE et al. Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ Res. 2005;96(4):412–8.PubMedCrossRef
72.
Majumdar V, Nagaraja D, Christopher R. Association of the functional KL-VS variant of Klotho gene with early-onset ischemic stroke. Biochem Biophys Res Commun. 2010;403(3–4):412–6.PubMedCrossRef
73.
Vaziri ND et al. Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol Dial Transplant. 2012;27(7):2686–93.PubMedCrossRef
74.
75.
Szeto CC et al. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol. 2008;3(2):431–6.PubMedPubMedCentralCrossRef
76.
Feroze U et al. Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Ren Nutr. 2012;22(3):317–26.PubMedCrossRef
77.
Vaziri ND, Yuan J, Norris K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol. 2013;37(1):1–6.PubMedCrossRef
78.
Lau WL, et al. Role of Nrf2 dysfunction in uremia-associated intestinal inflammation and epithelial barrier disruption. Dig Dis Sci. 2014;60:1215–2.
79.
Rossi M et al. Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3–4 chronic kidney disease. Arch Med Res. 2014;45(4):309–17.PubMedCrossRef
80.
Tang WH et al. Gut microbiota-dependent Trimethylamine N-Oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448–55.PubMedCrossRef
81.
Chung DW et al. Systemic administration of lipopolysaccharide induces cyclooxygenase-2 immunoreactivity in endothelium and increases microglia in the mouse hippocampus. Cell Mol Neurobiol. 2010;30(4):531–41.PubMedCrossRef
82.
Liu S et al. Comparative analysis of H&E and Prussian blue staining in a mouse model of cerebral microbleeds. J Histochem Cytochem. 2014;62(11):767–73.PubMedCrossRef
83.
Yin J et al. Dysbiosis of gut microbiota with reduced trimethylamine-N-oxide level in patients with large-artery atherosclerotic stroke or transient ischemic attack. J Am Heart Assoc. 2015;4(11):e002699.PubMedPubMedCentralCrossRef
84.
Bomback AS, Bakris GL. Chronic kidney disease (CKD) and hypertension essentials. Boston, Massachusetts: Jones & Bartlett Learning; 2010.
85.
Lee JM et al. Vascular permeability precedes spontaneous intracerebral hemorrhage in stroke-prone spontaneously hypertensive rats. Stroke. 2007;38(12):3289–91.PubMedCrossRef
86.
Jaimes EA et al. Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species. Am J Physiol Renal Physiol. 2008;294(2):F385–92.PubMedCrossRef
87.
Zhou MS, Schulman IH, Raij L. Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: role of nuclear factor kappa B activation. J Hypertens. 2010;28(3):527–35.PubMedCrossRef
88.
Ritz MF et al. Identification of inflammatory, metabolic, and cell survival pathways contributing to cerebral small vessel disease by postmortem gene expression microarray. Curr Neurovasc Res. 2016;13(1):58–67.PubMedCrossRef
89.
90.
Lin J et al. Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial. Diabetes Care. 2008;31(12):2338–43.PubMedPubMedCentralCrossRef
91.
92.
93.
Lee DB, Huang E, Ward HJ. Tight junction biology and kidney dysfunction. Am J Physiol Renal Physiol. 2006;290(1):F20–34.PubMedCrossRef
94.
95.
Wardlaw JM et al. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke. 2003;34(3):806–12.PubMedCrossRef
96.
Jeppsson B et al. Blood-brain barrier derangement in uremic encephalopathy. Surgery. 1982;92(1):30–5.PubMed
97.
98.
Perez-Rodriguez J et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment—report of 33 cases. Radiology. 2009;250(2):371–7.PubMedPubMedCentralCrossRef
99.
Morris JM, Miller GM. Increased signal in the subarachnoid space on fluid-attenuated inversion recovery imaging associated with the clearance dynamics of gadolinium chelate: a potential diagnostic pitfall. AJNR Am J Neuroradiol. 2007;28(10):1964–7.PubMedCrossRef
100.
Rai AT, Hogg JP. Persistence of gadolinium in CSF: a diagnostic pitfall in patients with end-stage renal disease. AJNR Am J Neuroradiol. 2001;22(7):1357–61.PubMed
101.
Stinghen AE et al. Differential effects of indoxyl sulfate and inorganic phosphate in a murine cerebral endothelial cell line (bEnd.3). Toxins (Basel). 2014;6(6):1742–60.CrossRef
102.
103.
104.
Dou L et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost. 2007;5(6):1302–8.PubMedCrossRef
105.
Shimizu H et al. Indoxyl sulfate upregulates renal expression of ICAM-1 via production of ROS and activation of NF-kB and p53 in proximal tubular cells. Life Sci. 2013;92(2):143–8.PubMedCrossRef
106.
Ryu JH, Kim SJ. Clopidogrel effectively suppresses endothelial microparticle generation induced by indoxyl sulfate via inhibition of the p38 mitogen-activated protein kinase pathway. Blood Purif. 2011;32(3):186–94.PubMedCrossRef
107.
Meijers BK et al. The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis. 2009;54(5):891–901.PubMedCrossRef
108.
Peng YS et al. Effects of indoxyl sulfate on adherens junctions of endothelial cells and the underlying signaling mechanism. J Cell Biochem. 2012;113(3):1034–43.PubMedCrossRef
109.
Fazekas F et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol. 1999;20(4):637–42.PubMed
110.
Shoamanesh A, Kwok CS, Benavente O. Cerebral microbleeds: histopathological correlation of neuroimaging. Cerebrovasc Dis. 2011;32(6):528–34.PubMedCrossRef
111.
Li L et al. Cerebral microbleeds and cognitive decline in a hemodialysis patient: case report and review of literature. Hemodial Int. 2015;19(3):E1–7.PubMedCrossRef
112.
van Norden AG et al. Frontal and temporal microbleeds are related to cognitive function: the Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort (RUN DMC) Study. Stroke. 2011;42(12):3382–6.PubMedCrossRef
113.
Poels MM et al. Cerebral microbleeds are associated with worse cognitive function: the Rotterdam Scan Study. Neurology. 2012;78(5):326–33.PubMedCrossRef
114.
Wardlaw JM et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822–38.PubMedPubMedCentralCrossRef
115.
Shima H et al. Cerebral microbleeds in predialysis patients with chronic kidney disease. Nephrol Dial Transplant. 2010;25(5):1554–9.PubMedCrossRef
116.
Naganuma T et al. Cerebral microbleeds predict intracerebral hemorrhage in hemodialysis patients. Stroke. 2015;46(8):2107–12.PubMedCrossRef
117.
Xiao L et al. Correlation between cerebral microbleeds and S100B/RAGE in acute lacunar stroke patients. J Neurol Sci. 2014;340(1–2):208–12.PubMedCrossRef
118.
Charidimou A, Werring DJ. A raging fire in acute lacunar stroke: inflammation, blood-brain barrier dysfunction and the origin of cerebral microbleeds. J Neurol Sci. 2014;340(1–2):1–2.PubMedCrossRef
119.
Isoyama N et al. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients. Nephrol Dial Transplant. 2015;30(1):84–91.PubMedCrossRef
120.
Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial. 2006;19(4):317–22.PubMedCrossRef
121.
Cases A et al. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int. 1992;42(3):668–72.PubMedCrossRef
122.
Diaz-Ricart M et al. Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients. Thromb Haemost. 1999;82(4):1312–7.PubMed
Metadata
Title
The Cerebrovascular-Chronic Kidney Disease Connection: Perspectives and Mechanisms
Authors
Wei Ling Lau
Branko N. Huisa
Mark Fisher
Publication date
01-02-2017
Publisher
Springer US
Published in
Translational Stroke Research / Issue 1/2017
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI
https://doi.org/10.1007/s12975-016-0499-x

Other articles of this Issue 1/2017

Translational Stroke Research 1/2017 Go to the issue

SI: Present and future of neuroplasticity in CNS recovery

Neurogenesis in Stroke Recovery

Original Article

Mechanisms of Axonal Damage and Repair after Central Nervous System Injury

SI: Present and future of neuroplasticity in CNS recovery

Spontaneous and Therapeutic-Induced Mechanisms of Functional Recovery After Stroke

SI: Present and future of neuroplasticity in CNS recovery

The Plasminogen Activation System Promotes Dendritic Spine Recovery and Improvement in Neurological Function After an Ischemic Stroke

Commentary

Correcting the Trajectory of Stroke Therapeutic Research

Original Article

Interactive Voice Response—An Innovative Approach to Post-Stroke Depression Self-Management Support